Immune Design Corp. (NASDAQ:IMDZ) – Equities research analysts at Leerink Swann increased their FY2017 EPS estimates for shares of Immune Design Corp. in a research note issued on Wednesday. Leerink Swann analyst J. Chang now forecasts that the biotechnology company will post earnings per share of ($1.81) for the year, up from their prior forecast of ($2.54). Leerink Swann also issued estimates for Immune Design Corp.’s Q4 2017 earnings at ($0.34) EPS and FY2018 earnings at ($1.38) EPS.
Several other equities research analysts have also recently weighed in on the company. ValuEngine cut Immune Design Corp. from a “sell” rating to a “strong sell” rating in a report on Saturday, October 21st. Wells Fargo & Company cut Immune Design Corp. from an “outperform” rating to a “market perform” rating and dropped their target price for the company from $29.00 to $10.00 in a report on Tuesday, October 17th. Royal Bank Of Canada assumed coverage on Immune Design Corp. in a report on Thursday, September 14th. They set an “outperform” rating and a $20.00 target price for the company. BidaskClub cut Immune Design Corp. from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 5th. Finally, Zacks Investment Research upgraded Immune Design Corp. from a “hold” rating to a “buy” rating and set a $11.00 target price for the company in a report on Tuesday, July 18th. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company. Immune Design Corp. has a consensus rating of “Buy” and a consensus price target of $14.75.
Shares of Immune Design Corp. (NASDAQ:IMDZ) opened at $4.15 on Monday. Immune Design Corp. has a fifty-two week low of $3.78 and a fifty-two week high of $13.05.
Immune Design Corp. (NASDAQ:IMDZ) last posted its quarterly earnings data on Wednesday, November 1st. The biotechnology company reported ($0.52) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.63) by $0.11. The firm had revenue of $0.52 million during the quarter, compared to analysts’ expectations of $0.62 million. Immune Design Corp. had a negative return on equity of 68.69% and a negative net margin of 619.62%.
In other Immune Design Corp. news, Director Peter Svennilson purchased 2,681,000 shares of the stock in a transaction on Friday, October 27th. The stock was acquired at an average price of $4.10 per share, with a total value of $10,992,100.00. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Also, major shareholder Leo Guthart purchased 10,000 shares of the stock in a transaction on Monday, September 18th. The shares were acquired at an average cost of $9.70 per share, with a total value of $97,000.00. The disclosure for this purchase can be found here. Insiders have purchased a total of 5,250,000 shares of company stock valued at $21,649,900 over the last 90 days. 20.70% of the stock is currently owned by company insiders.
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Bank of America Corp DE raised its position in Immune Design Corp. by 123.3% during the 1st quarter. Bank of America Corp DE now owns 15,246 shares of the biotechnology company’s stock valued at $104,000 after purchasing an additional 8,418 shares during the last quarter. State of Wisconsin Investment Board bought a new position in Immune Design Corp. during the 2nd quarter valued at approximately $117,000. Alliancebernstein L.P. bought a new position in Immune Design Corp. during the 2nd quarter valued at approximately $118,000. Virtu KCG Holdings LLC bought a new position in Immune Design Corp. during the 2nd quarter valued at approximately $153,000. Finally, Dimensional Fund Advisors LP raised its position in Immune Design Corp. by 9.3% during the 2nd quarter. Dimensional Fund Advisors LP now owns 18,896 shares of the biotechnology company’s stock valued at $184,000 after purchasing an additional 1,600 shares during the last quarter. 51.76% of the stock is owned by institutional investors and hedge funds.
Immune Design Corp. Company Profile
Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company has engineered its technologies to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells (CTLs) to fight cancer.
What are top analysts saying about Immune Design Corp.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Immune Design Corp. and related companies.